BLOOD WORK: WHAT TO TEST BEFORE AND DURING A CYCLE

1.The pre-cycle baseline panel

Before starting any peptide protocol, establish a complete metabolic and hormonal baseline. Minimum panel: Complete Metabolic Panel (CMP — covers glucose, kidney function, liver enzymes, electrolytes), lipid panel (total cholesterol, LDL, HDL, triglycerides), Complete Blood Count (CBC), and fasting glucose.

For GH peptide protocols specifically, add IGF-1 and fasting insulin to the minimum panel. IGF-1 is the primary biomarker for GH peptide efficacy — it reflects average GH activity over the preceding weeks. Your pre-cycle IGF-1 tells you where your GH axis starts. A low baseline (below age-appropriate reference range) provides clear room for improvement and makes the case for GH peptide therapy most compelling. A high-normal baseline means the protocol may produce less dramatic effects.

For GLP-1 protocols, add HbA1c (hemoglobin A1c, a 3-month average of blood glucose) to the minimum panel. GLP-1 agonists dramatically improve glucose control — HbA1c before and after provides the most comprehensive picture of metabolic improvement beyond just weight loss.

For anyone over 35: add testosterone (total and free) and TSH (thyroid stimulating hormone). Thyroid and testosterone dysfunction are common and produce symptoms that overlap with peptide protocol side effects — knowing your baseline eliminates confusion if symptoms change during the protocol.

Where to get bloodwork without a doctor's order: direct-to-consumer lab services (Ulta Lab Tests, Any Lab Test Now, PrivateMD Labs in the US) allow ordering your own blood panels without a physician referral. Prices are significantly lower than through insurance billing. Quest Diagnostics and LabCorp are the most common processing labs for these services. Many panels can be ordered online and drawn at a local patient service center.

Record the specific values, reference ranges, and draw date for every baseline result. Keep this in your protocol log alongside your injection records. These numbers are useless if you cannot find them mid-cycle.

2.GH peptide monitoring: what to test and when

Test again at week 6-8 of a GH peptide protocol. The two primary markers: IGF-1 (should be elevated from baseline) and fasting glucose (should not have risen significantly from baseline).

IGF-1 elevation from baseline: a working GH peptide protocol at standard doses typically raises IGF-1 by 30-100 ng/mL. Elevation of 50+ ng/mL is a clear positive signal. If IGF-1 has not moved from baseline at week 8, consider: (1) Are you eating within 2 hours of injection? Food/insulin blunts GH release and is the most common cause of a non-working protocol. (2) Is the dose sufficient? (3) Is the product quality adequate? Community testing of your vendor's products is relevant here.

IGF-1 target range: the goal is to bring IGF-1 to the upper portion of the normal range for your age — not to push it above the reference range. Reference ranges decrease with age. For a 40-year-old, the reference range might be 95-310 ng/mL; the target is 280-310, not 400. Exceeding the reference range raises legitimate concerns about acromegaly-like effects with prolonged exposure.

Fasting glucose monitoring: a rise in fasting glucose above 100 mg/dL from a lower baseline, or by more than 10-15 mg/dL from an already-normal baseline, is a signal to reduce GH peptide dose. GH's insulin-antagonistic effects are real and dose-dependent. For users who already have impaired fasting glucose (100-125 mg/dL) or prediabetes, GH peptides require particularly careful glucose monitoring and may not be appropriate without medical supervision.

Post-cycle testing: test IGF-1 and fasting glucose 4-6 weeks after stopping the protocol to confirm both markers return to baseline. This confirms that the metabolic changes from the protocol are reversible and gives you a clean baseline for the next cycle.

3.GLP-1 specific monitoring

For semaglutide or tirzepatide protocols, the primary monitoring framework is weight, body composition, and glucose metabolism markers. Weight should be tracked weekly (7-day rolling average). Body measurements monthly. HbA1c before and after a 16-week protocol provides the most comprehensive picture of metabolic improvement.

Lipid panel after 12-16 weeks of GLP-1 use typically shows significant improvements with weight loss: LDL usually decreases 10-15%, HDL increases 5-10%, and triglycerides often fall substantially (20-40%). These improvements often lag weight loss by 4-8 weeks, so testing at week 16 rather than week 8 captures them better.

Muscle preservation marker: checking a DEXA scan before and after is the gold standard for tracking fat mass vs lean mass changes. Many imaging centers offer DEXA without a prescription. If DEXA is not accessible, circumference measurements (upper arm, thigh) alongside scale weight provide a reasonable proxy — if circumference is maintained while weight decreases, lean mass is being preserved.

Amylase and lipase: some practitioners baseline these enzymes and retest if GI side effects are particularly severe. Pancreatitis risk with GLP-1 agonists, while rare, produces amylase and lipase elevation. However, GLP-1 agonists also cause mild pancreatic enzyme elevation without pancreatitis — so interpretation of mildly elevated results requires clinical context. Only clinically significant elevation (3-5x upper limit of normal) combined with abdominal pain suggests pancreatitis.

Thyroid function: GLP-1 agonists are contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). TSH before starting a GLP-1 protocol and any clinical concern about thyroid nodules should be discussed with a physician. The thyroid risk is primarily a precaution based on rodent study findings; the clinical risk in humans has not been established but the contraindication stands pending further evidence.

4.Reading results in context

Reference ranges are population-based averages that define the range within which 95% of apparently healthy people fall. Being in-range does not mean optimal — being in the upper or lower 5% of 'normal' may still represent suboptimal function for you specifically. The goal of monitoring is to understand your trend, not just whether you are technically in range.

Interpreting IGF-1 by age: 20-30 year olds: 120-400 ng/mL. 30-40 year olds: 115-355. 40-50: 95-310. 50-60: 88-265. Age-adjusted reference ranges matter more than absolute numbers. A 45-year-old with IGF-1 of 350 ng/mL is at the upper end of their range, which is fine and expected with a well-functioning GH peptide protocol. The same number in a 25-year-old is within normal range.

Day-of-draw considerations: IGF-1 is a stable marker — it reflects average GH activity over days, not hours. The timing of your last injection relative to blood draw matters less for IGF-1 than it would for direct GH measurement. Draw IGF-1 at your regular time; morning draws are conventional. Fasting glucose must be fasted (8+ hours, no caloric intake) — non-fasting glucose values are not interpretable for baseline comparison.

When results surprise you: unexpected elevation in liver enzymes (AST, ALT) mid-cycle is a signal to investigate further — some compounds can affect liver function, and very high training volumes also elevate liver enzymes from muscle damage. A transient ALT of 1.5x upper limit of normal is generally not concerning; persistent elevation above 3x upper limit of normal warrants stopping the protocol and consulting a physician.

Bring your logged protocol data to any physician consultation: exactly what you took, at what doses, for how long, and what your symptoms were. This is the information a physician needs to make sense of laboratory findings in the context of peptide use. 'I was taking some supplements' is not useful; a log with dates and doses is.